Welcome to our dedicated page for Zenas BioPharma SEC filings (Ticker: ZBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Zenas BioPharma, Inc. (Nasdaq: ZBIO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Zenas is a clinical-stage global biopharmaceutical company focused on therapies for autoimmune diseases, and its filings document key aspects of its business, including stock exchange listing details, financing arrangements, licensing agreements and clinical development updates.
Recent Form 8-K filings describe material events such as the revenue participation and funding agreement with Royalty Pharma related to obexelimab, under which Royalty Pharma will provide up to $300 million in consideration in exchange for specified royalty and revenue participation rights. Other 8-Ks detail the license agreement with InnoCare Pharma granting Zenas exclusive rights to develop, manufacture and commercialize orelabrutinib in the multiple sclerosis field globally and non-oncology indications outside certain territories, as well as rights to ZB021 and ZB022. Additional current reports cover private placement financings, adoption of the 2026 Inducement Plan for equity awards, and press releases furnishing quarterly financial results.
Through this page, users can review how Zenas reports its status as an emerging growth company, its listing of common stock on The Nasdaq Global Select Market under the symbol ZBIO, and the terms of material definitive agreements that shape its capital structure and pipeline strategy. Filings linked here include exhibits such as inducement equity plans, option and restricted stock unit agreements, subscription and registration rights agreements, and revenue participation contracts, which provide further detail on governance and compensation frameworks.
Stock Titan enhances these documents with AI-powered summaries that explain the significance of each filing in clear language. As new 8-Ks, 10-Qs, 10-Ks and other forms become available on EDGAR, they are incorporated so investors can quickly see how developments in obexelimab, orelabrutinib, ZB021 and ZB022, as well as financing and licensing transactions, are reflected in Zenas BioPharma’s official regulatory record.
Zenas BioPharma director Jason Raleigh Nunn was granted stock options for 18,500 shares of Common Stock. The options have an exercise price of $18.71 per share and expire on June 15, 2036. They vest entirely on June 15, 2027, contingent on continued service.
Zenas BioPharma, Inc. director Hongbo Lu received a grant of stock options covering 18,500 shares of common stock. The options have an exercise price of $18.71 per share, expire on June 15, 2036, and will vest 100% on June 15, 2027, subject to continued service.
Zenas BioPharma, Inc. director and officer Leon O. Moulder Jr. reported a grant of stock options covering 500,000 shares of common stock. The options have an exercise price of $18.71 per share and expire on June 15, 2036.
According to the disclosure, 25% of the underlying shares vest on June 15, 2027, with the remaining shares vesting in equal monthly installments over the following 36 months, subject to continued service. Following this grant, Moulder holds 500,000 stock options directly.
Zenas BioPharma, Inc. reported that director John J. Orloff received a grant of stock options covering 18,500 shares of common stock. The options have an exercise price of $18.71 per share and expire on June 15, 2036.
According to the disclosure, the option vests as to 100% of the underlying 18,500 shares on June 15, 2027, the first anniversary of the vesting commencement date, subject to continued service. Following this grant, Orloff holds options for 18,500 shares directly.
Zenas BioPharma, Inc. reported that officer Lisa von Moltke received a grant of stock options covering 150,000 shares of common stock. The options have an exercise price of $18.71 per share and expire on June 15, 2036.
The grant vests as to 25% of the underlying shares on June 15, 2027, the first anniversary of the vesting commencement date. The remaining 75% vests in equal monthly installments over the following 36 months, subject to her continued service. Following this award, she holds 150,000 stock options directly.
Zenas BioPharma, Inc. reported that director Patricia L. Allen received a grant of stock options covering 18,500 shares of common stock. The options have an exercise price of $18.71 per share and expire on June 15, 2036. They vest in full on June 15, 2027, subject to continued service.
Zenas BioPharma, Inc. reported a Form 4 showing director James P. Boylan received a grant of stock options covering 18,500 shares of common stock at an exercise price of $18.71 per share. These options were awarded as compensation rather than through an open-market purchase.
The option vests as to 100% of the underlying 18,500 shares on June 15, 2027, subject to Boylan’s continued service. The options expire on June 15, 2036, providing a long exercise window. The filing notes Boylan holds the option for the benefit of Enavate Sciences, L.P. and disclaims beneficial ownership except for any pecuniary interest. Following this grant, 18,500 derivative securities are reported as held directly.
Zenas BioPharma, Inc. director Patrick G. Enright reported receiving a grant of stock options covering 18,500 shares of common stock at an exercise price of $18.71 per share. The options were awarded as compensation and are held directly.
The option vests as to 100% of the 18,500 underlying shares on June 15, 2027, subject to his continued service, and expires on June 15, 2036. No open-market purchase or sale of Zenas BioPharma common stock was reported in this filing.
Zenas BioPharma, Inc. reported that officer Joseph L. Farmer received equity-based compensation. He was granted stock options for 175,000 shares of common stock at an exercise price of $18.71 per share, expiring on June 15, 2036, and acquired 974 shares of common stock through the 2024 Employee Stock Purchase Plan at $13.35 per share.
Zenas BioPharma, Inc. reported that officer Jennifer A. Fox received equity awards in the form of an option grant and common shares. On June 15, 2026, she was granted 125,000 stock options to buy common stock at $18.71 per share, expiring on June 15, 2036. The option vests 25% on June 15, 2027, then in equal monthly installments over the following 36 months, subject to continued service. On February 5, 2026, she also acquired 1,592 common shares at $13.35 under the company’s 2024 Employee Stock Purchase Plan in transactions exempt under Rule 16b-3(c).